Mineralocorticoid receptor antagonists (MRAs) are primarily included in the standard management of heart failure (HF) and hypertension, yet they have been shown to delay the progression of CKD in patients with hypertension and/or HF and proteinuria [11–13]. Here, NR3C2 is linked to hypertensive disorder.